Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine
This study was planned to evaluate whether a 3-month treatment with Lactobacillus rhamnosus GG (LGG) can modify immune system functions in children and adolescents with type 1 diabetes (T1D), leading to an increased immune response to an injectable quadrivalent inactivated influenza vaccine (QIV). A...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2020-01, Vol.16 (1), p.86-94 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 94 |
|---|---|
| container_issue | 1 |
| container_start_page | 86 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 16 |
| creator | Bianchini, Sonia Orabona, Ciriana Camilloni, Barbara Berioli, Maria Giulia Argentiero, Alberto Matino, Davide Alunno, Anna Albini, Elisa Vacca, Carmine Pallotta, Maria Teresa Mancini, Giulia Tascini, Giorgia Toni, Giada Mondanelli, Giada Silvestri, Ettore Grohmann, Ursula Esposito, Susanna |
| description | This study was planned to evaluate whether a 3-month treatment with Lactobacillus rhamnosus GG (LGG) can modify immune system functions in children and adolescents with type 1 diabetes (T1D), leading to an increased immune response to an injectable quadrivalent inactivated influenza vaccine (QIV). A total of 87 pediatric patients with T1D were screened, although 34 patients in the Probiotic group and 30 in the Control group accepted to be vaccinated with QIV and completed the study. Vaccine immunogenicity and safety and the inflammatory cytokine response were studied. Results showed that QIV was immunogenic and safe in T1D pediatric patients and pre-administration of LGG for three months did not substantially modify the QIV humoral immunity. The combination of QIV and LGG reduced inflammatory responses (i.e., IFN-γ, IL17A, IL-17F, IL-6, and TNF-α) from activated PBMCs of pediatric patients with T1D, without dampening the production of seroprotective antibodies. In conclusion, QIV is associated with an adequate immunogenicity in children and adolescents with T1D in presence of a good safety profile. Although a systematic administration of LGG did not result in an improvement of humoral responses to an influenza vaccine, the probiotic did induce important anti-inflammatory effects. |
| doi_str_mv | 10.1080/21645515.2019.1633877 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7012143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_829570c5e15849b182a855397f4da2c4</doaj_id><sourcerecordid>2242815976</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-89299b71ab17624e2ac50d6d97cc7d54cc8df515db77932b869a0919b1fcf5463</originalsourceid><addsrcrecordid>eNp9Uk1vGyEQXVWtmijNT2jFsRc7wMKyXKpWUdpGipRLK_WGZvmIiXbBAdaR-0v6c4tjx2ouRUgMw3tvRsNrmvcELwnu8QUlHeOc8CXFRC5J17a9EK-a011-wTn79foYE37SnOd8j-sSmLKue9uctIQSzLk4bf5cOWd1ySg6tE5x8LF4jcBMPvhcEhQfA6rbT9McLEo2r2PI9gmvV340yQYEwVRKHG3WNlStR19WqGzXFhFkPAy2VEKJCNDDDCb5DYwVh3wAXeqlWFNjN842_Aa0Aa19sO-aNw7GbM8P51nz8-vVj8vvi5vbb9eXX24WmresLHpJpRwEgYGIjjJLQXNsOiOF1sJwpnVvXB2CGYSQLR36TgKWRA7EacdZ154113tdE-FerZOfIG1VBK-eEjHdKUh1JqNVPZVcYM0t4T2rCj2FnvNWCscMUM2q1qe91noeJmt2w0gwvhB9-RL8St3FjRK4fghrq8DHg0CKD7PNRU2-znQcIdg4Z0Upoz3hUuz65nuoTjHnZN2xDMFqZxL1bBK1M4k6mKTyPvzb45H1bIkK-LwH1C-JaYLHmEajCmzHmFyCoH2u4P_W-AuXfs8K</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242815976</pqid></control><display><type>article</type><title>Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Bianchini, Sonia ; Orabona, Ciriana ; Camilloni, Barbara ; Berioli, Maria Giulia ; Argentiero, Alberto ; Matino, Davide ; Alunno, Anna ; Albini, Elisa ; Vacca, Carmine ; Pallotta, Maria Teresa ; Mancini, Giulia ; Tascini, Giorgia ; Toni, Giada ; Mondanelli, Giada ; Silvestri, Ettore ; Grohmann, Ursula ; Esposito, Susanna</creator><creatorcontrib>Bianchini, Sonia ; Orabona, Ciriana ; Camilloni, Barbara ; Berioli, Maria Giulia ; Argentiero, Alberto ; Matino, Davide ; Alunno, Anna ; Albini, Elisa ; Vacca, Carmine ; Pallotta, Maria Teresa ; Mancini, Giulia ; Tascini, Giorgia ; Toni, Giada ; Mondanelli, Giada ; Silvestri, Ettore ; Grohmann, Ursula ; Esposito, Susanna</creatorcontrib><description>This study was planned to evaluate whether a 3-month treatment with Lactobacillus rhamnosus GG (LGG) can modify immune system functions in children and adolescents with type 1 diabetes (T1D), leading to an increased immune response to an injectable quadrivalent inactivated influenza vaccine (QIV). A total of 87 pediatric patients with T1D were screened, although 34 patients in the Probiotic group and 30 in the Control group accepted to be vaccinated with QIV and completed the study. Vaccine immunogenicity and safety and the inflammatory cytokine response were studied. Results showed that QIV was immunogenic and safe in T1D pediatric patients and pre-administration of LGG for three months did not substantially modify the QIV humoral immunity. The combination of QIV and LGG reduced inflammatory responses (i.e., IFN-γ, IL17A, IL-17F, IL-6, and TNF-α) from activated PBMCs of pediatric patients with T1D, without dampening the production of seroprotective antibodies. In conclusion, QIV is associated with an adequate immunogenicity in children and adolescents with T1D in presence of a good safety profile. Although a systematic administration of LGG did not result in an improvement of humoral responses to an influenza vaccine, the probiotic did induce important anti-inflammatory effects.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2019.1633877</identifier><identifier>PMID: 31210557</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Adolescent ; Antibodies, Viral - blood ; Child ; Child, Preschool ; Cytokines - immunology ; Diabetes Mellitus, Type 1 - immunology ; Female ; Humans ; Immunity, Humoral ; Immunogenicity, Vaccine ; Infant ; Inflammation - prevention & control ; influenza ; influenza vaccine ; Influenza Vaccines - administration & dosage ; Influenza Vaccines - immunology ; Influenza, Human - prevention & control ; Lactobacillus GG ; Lactobacillus rhamnosus - immunology ; Male ; probiotic ; Probiotics - administration & dosage ; proinflammatory cytokines ; Prospective Studies ; Research Paper ; Single-Blind Method ; type 1 diabetes (T1D) ; Vaccines, Inactivated - administration & dosage ; Vaccines, Inactivated - immunology</subject><ispartof>Human vaccines & immunotherapeutics, 2020-01, Vol.16 (1), p.86-94</ispartof><rights>2019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019</rights><rights>2019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-89299b71ab17624e2ac50d6d97cc7d54cc8df515db77932b869a0919b1fcf5463</citedby><cites>FETCH-LOGICAL-c534t-89299b71ab17624e2ac50d6d97cc7d54cc8df515db77932b869a0919b1fcf5463</cites><orcidid>0000-0003-4103-2837 ; 0000-0002-0798-0465 ; 0000-0002-3799-8164 ; 0000-0001-7952-1850</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012143/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012143/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31210557$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bianchini, Sonia</creatorcontrib><creatorcontrib>Orabona, Ciriana</creatorcontrib><creatorcontrib>Camilloni, Barbara</creatorcontrib><creatorcontrib>Berioli, Maria Giulia</creatorcontrib><creatorcontrib>Argentiero, Alberto</creatorcontrib><creatorcontrib>Matino, Davide</creatorcontrib><creatorcontrib>Alunno, Anna</creatorcontrib><creatorcontrib>Albini, Elisa</creatorcontrib><creatorcontrib>Vacca, Carmine</creatorcontrib><creatorcontrib>Pallotta, Maria Teresa</creatorcontrib><creatorcontrib>Mancini, Giulia</creatorcontrib><creatorcontrib>Tascini, Giorgia</creatorcontrib><creatorcontrib>Toni, Giada</creatorcontrib><creatorcontrib>Mondanelli, Giada</creatorcontrib><creatorcontrib>Silvestri, Ettore</creatorcontrib><creatorcontrib>Grohmann, Ursula</creatorcontrib><creatorcontrib>Esposito, Susanna</creatorcontrib><title>Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>This study was planned to evaluate whether a 3-month treatment with Lactobacillus rhamnosus GG (LGG) can modify immune system functions in children and adolescents with type 1 diabetes (T1D), leading to an increased immune response to an injectable quadrivalent inactivated influenza vaccine (QIV). A total of 87 pediatric patients with T1D were screened, although 34 patients in the Probiotic group and 30 in the Control group accepted to be vaccinated with QIV and completed the study. Vaccine immunogenicity and safety and the inflammatory cytokine response were studied. Results showed that QIV was immunogenic and safe in T1D pediatric patients and pre-administration of LGG for three months did not substantially modify the QIV humoral immunity. The combination of QIV and LGG reduced inflammatory responses (i.e., IFN-γ, IL17A, IL-17F, IL-6, and TNF-α) from activated PBMCs of pediatric patients with T1D, without dampening the production of seroprotective antibodies. In conclusion, QIV is associated with an adequate immunogenicity in children and adolescents with T1D in presence of a good safety profile. Although a systematic administration of LGG did not result in an improvement of humoral responses to an influenza vaccine, the probiotic did induce important anti-inflammatory effects.</description><subject>Adolescent</subject><subject>Antibodies, Viral - blood</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cytokines - immunology</subject><subject>Diabetes Mellitus, Type 1 - immunology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunity, Humoral</subject><subject>Immunogenicity, Vaccine</subject><subject>Infant</subject><subject>Inflammation - prevention & control</subject><subject>influenza</subject><subject>influenza vaccine</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza Vaccines - immunology</subject><subject>Influenza, Human - prevention & control</subject><subject>Lactobacillus GG</subject><subject>Lactobacillus rhamnosus - immunology</subject><subject>Male</subject><subject>probiotic</subject><subject>Probiotics - administration & dosage</subject><subject>proinflammatory cytokines</subject><subject>Prospective Studies</subject><subject>Research Paper</subject><subject>Single-Blind Method</subject><subject>type 1 diabetes (T1D)</subject><subject>Vaccines, Inactivated - administration & dosage</subject><subject>Vaccines, Inactivated - immunology</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9Uk1vGyEQXVWtmijNT2jFsRc7wMKyXKpWUdpGipRLK_WGZvmIiXbBAdaR-0v6c4tjx2ouRUgMw3tvRsNrmvcELwnu8QUlHeOc8CXFRC5J17a9EK-a011-wTn79foYE37SnOd8j-sSmLKue9uctIQSzLk4bf5cOWd1ySg6tE5x8LF4jcBMPvhcEhQfA6rbT9McLEo2r2PI9gmvV340yQYEwVRKHG3WNlStR19WqGzXFhFkPAy2VEKJCNDDDCb5DYwVh3wAXeqlWFNjN842_Aa0Aa19sO-aNw7GbM8P51nz8-vVj8vvi5vbb9eXX24WmresLHpJpRwEgYGIjjJLQXNsOiOF1sJwpnVvXB2CGYSQLR36TgKWRA7EacdZ154113tdE-FerZOfIG1VBK-eEjHdKUh1JqNVPZVcYM0t4T2rCj2FnvNWCscMUM2q1qe91noeJmt2w0gwvhB9-RL8St3FjRK4fghrq8DHg0CKD7PNRU2-znQcIdg4Z0Upoz3hUuz65nuoTjHnZN2xDMFqZxL1bBK1M4k6mKTyPvzb45H1bIkK-LwH1C-JaYLHmEajCmzHmFyCoH2u4P_W-AuXfs8K</recordid><startdate>20200102</startdate><enddate>20200102</enddate><creator>Bianchini, Sonia</creator><creator>Orabona, Ciriana</creator><creator>Camilloni, Barbara</creator><creator>Berioli, Maria Giulia</creator><creator>Argentiero, Alberto</creator><creator>Matino, Davide</creator><creator>Alunno, Anna</creator><creator>Albini, Elisa</creator><creator>Vacca, Carmine</creator><creator>Pallotta, Maria Teresa</creator><creator>Mancini, Giulia</creator><creator>Tascini, Giorgia</creator><creator>Toni, Giada</creator><creator>Mondanelli, Giada</creator><creator>Silvestri, Ettore</creator><creator>Grohmann, Ursula</creator><creator>Esposito, Susanna</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4103-2837</orcidid><orcidid>https://orcid.org/0000-0002-0798-0465</orcidid><orcidid>https://orcid.org/0000-0002-3799-8164</orcidid><orcidid>https://orcid.org/0000-0001-7952-1850</orcidid></search><sort><creationdate>20200102</creationdate><title>Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine</title><author>Bianchini, Sonia ; Orabona, Ciriana ; Camilloni, Barbara ; Berioli, Maria Giulia ; Argentiero, Alberto ; Matino, Davide ; Alunno, Anna ; Albini, Elisa ; Vacca, Carmine ; Pallotta, Maria Teresa ; Mancini, Giulia ; Tascini, Giorgia ; Toni, Giada ; Mondanelli, Giada ; Silvestri, Ettore ; Grohmann, Ursula ; Esposito, Susanna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-89299b71ab17624e2ac50d6d97cc7d54cc8df515db77932b869a0919b1fcf5463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Antibodies, Viral - blood</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cytokines - immunology</topic><topic>Diabetes Mellitus, Type 1 - immunology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunity, Humoral</topic><topic>Immunogenicity, Vaccine</topic><topic>Infant</topic><topic>Inflammation - prevention & control</topic><topic>influenza</topic><topic>influenza vaccine</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza Vaccines - immunology</topic><topic>Influenza, Human - prevention & control</topic><topic>Lactobacillus GG</topic><topic>Lactobacillus rhamnosus - immunology</topic><topic>Male</topic><topic>probiotic</topic><topic>Probiotics - administration & dosage</topic><topic>proinflammatory cytokines</topic><topic>Prospective Studies</topic><topic>Research Paper</topic><topic>Single-Blind Method</topic><topic>type 1 diabetes (T1D)</topic><topic>Vaccines, Inactivated - administration & dosage</topic><topic>Vaccines, Inactivated - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bianchini, Sonia</creatorcontrib><creatorcontrib>Orabona, Ciriana</creatorcontrib><creatorcontrib>Camilloni, Barbara</creatorcontrib><creatorcontrib>Berioli, Maria Giulia</creatorcontrib><creatorcontrib>Argentiero, Alberto</creatorcontrib><creatorcontrib>Matino, Davide</creatorcontrib><creatorcontrib>Alunno, Anna</creatorcontrib><creatorcontrib>Albini, Elisa</creatorcontrib><creatorcontrib>Vacca, Carmine</creatorcontrib><creatorcontrib>Pallotta, Maria Teresa</creatorcontrib><creatorcontrib>Mancini, Giulia</creatorcontrib><creatorcontrib>Tascini, Giorgia</creatorcontrib><creatorcontrib>Toni, Giada</creatorcontrib><creatorcontrib>Mondanelli, Giada</creatorcontrib><creatorcontrib>Silvestri, Ettore</creatorcontrib><creatorcontrib>Grohmann, Ursula</creatorcontrib><creatorcontrib>Esposito, Susanna</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bianchini, Sonia</au><au>Orabona, Ciriana</au><au>Camilloni, Barbara</au><au>Berioli, Maria Giulia</au><au>Argentiero, Alberto</au><au>Matino, Davide</au><au>Alunno, Anna</au><au>Albini, Elisa</au><au>Vacca, Carmine</au><au>Pallotta, Maria Teresa</au><au>Mancini, Giulia</au><au>Tascini, Giorgia</au><au>Toni, Giada</au><au>Mondanelli, Giada</au><au>Silvestri, Ettore</au><au>Grohmann, Ursula</au><au>Esposito, Susanna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2020-01-02</date><risdate>2020</risdate><volume>16</volume><issue>1</issue><spage>86</spage><epage>94</epage><pages>86-94</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>This study was planned to evaluate whether a 3-month treatment with Lactobacillus rhamnosus GG (LGG) can modify immune system functions in children and adolescents with type 1 diabetes (T1D), leading to an increased immune response to an injectable quadrivalent inactivated influenza vaccine (QIV). A total of 87 pediatric patients with T1D were screened, although 34 patients in the Probiotic group and 30 in the Control group accepted to be vaccinated with QIV and completed the study. Vaccine immunogenicity and safety and the inflammatory cytokine response were studied. Results showed that QIV was immunogenic and safe in T1D pediatric patients and pre-administration of LGG for three months did not substantially modify the QIV humoral immunity. The combination of QIV and LGG reduced inflammatory responses (i.e., IFN-γ, IL17A, IL-17F, IL-6, and TNF-α) from activated PBMCs of pediatric patients with T1D, without dampening the production of seroprotective antibodies. In conclusion, QIV is associated with an adequate immunogenicity in children and adolescents with T1D in presence of a good safety profile. Although a systematic administration of LGG did not result in an improvement of humoral responses to an influenza vaccine, the probiotic did induce important anti-inflammatory effects.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>31210557</pmid><doi>10.1080/21645515.2019.1633877</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4103-2837</orcidid><orcidid>https://orcid.org/0000-0002-0798-0465</orcidid><orcidid>https://orcid.org/0000-0002-3799-8164</orcidid><orcidid>https://orcid.org/0000-0001-7952-1850</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2020-01, Vol.16 (1), p.86-94 |
| issn | 2164-5515 2164-554X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7012143 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Adolescent Antibodies, Viral - blood Child Child, Preschool Cytokines - immunology Diabetes Mellitus, Type 1 - immunology Female Humans Immunity, Humoral Immunogenicity, Vaccine Infant Inflammation - prevention & control influenza influenza vaccine Influenza Vaccines - administration & dosage Influenza Vaccines - immunology Influenza, Human - prevention & control Lactobacillus GG Lactobacillus rhamnosus - immunology Male probiotic Probiotics - administration & dosage proinflammatory cytokines Prospective Studies Research Paper Single-Blind Method type 1 diabetes (T1D) Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - immunology |
| title | Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A23%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20probiotic%20administration%20on%20immune%20responses%20of%20children%20and%20adolescents%20with%20type%201%20diabetes%20to%20a%20quadrivalent%20inactivated%20influenza%20vaccine&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Bianchini,%20Sonia&rft.date=2020-01-02&rft.volume=16&rft.issue=1&rft.spage=86&rft.epage=94&rft.pages=86-94&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2019.1633877&rft_dat=%3Cproquest_pubme%3E2242815976%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242815976&rft_id=info:pmid/31210557&rft_doaj_id=oai_doaj_org_article_829570c5e15849b182a855397f4da2c4&rfr_iscdi=true |